Tarsus Pharmaceuticals's Earnings: A Preview
Portfolio Pulse from Benzinga Insights
Tarsus Pharmaceuticals (NASDAQ:TARS) is scheduled to release its quarterly earnings report on February 27, 2024, with an expected EPS of $-1.36. Analysts and investors are keen on whether the company will surpass this estimate and provide positive guidance for the next quarter. Historically, TARS has shown a mixed performance in beating EPS estimates, with a notable 12.2% share price increase following last quarter's earnings beat. Shares are currently trading at $31.7, reflecting a 111.04% increase over the last 52 weeks, indicating a positive outlook among long-term shareholders.
February 26, 2024 | 7:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tarsus Pharmaceuticals is anticipated to report an EPS of $-1.36 for the upcoming quarter. Historical data shows a positive reaction to earnings beats, with a significant share price increase following the last quarter's results. The stock has seen a 111.04% increase over the past year, indicating strong investor confidence.
Given TARS's history of positive share price movement following earnings beats and the significant year-over-year stock appreciation, there is a strong likelihood of a positive short-term impact if the company beats the EPS estimate again and provides favorable guidance. The historical data suggests that the market reacts positively to TARS's earnings announcements, especially when they exceed expectations.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100